

**Grants Awarded through Expression of Interest Process  
1 January 2020 to 30 September 2020**

<b>ANTIVIRAL STRATEGIES</b>	
Dr Thomas Angelovich	Developing novel drug delivery strategies to target myeloid reservoirs of HIV in the brain
A/Prof Michael Beard	Development of antiviral targets and drug strategies and tests for antiviral drug resistance and toxicity.
Dr Natalie Borg	Novel, host-directed, and selective anti-HIV agents
Dr Christina Cortez-Jugo	Targeted delivery of nanoparticles to CD4+ T cells to combat the viral reservoir
A/Prof David Harrich	Proof-of-concept that Nanoparticle facilitates delivery and effectiveness of antiretroviral drugs to combat HIV-1 replication in the brain and central nervous system
Dr Hongping Jin	Development of a vaginally administered anti-HIV microbicide nanosystem
Prof Johnson Mak	Repurposing widely prescribed and safe drugs to block the establishment of HIV latent macrophages reservoir
Prof Simon Moulton	Development of lactic acid polymer coating for fabrication of multiple API delivery from over the counter intravaginal rings (OTC IVRs)
Prof Gilda Tachedjian	Optimisation of a gel for enhancing the vaginal environment and microbiome (EVE-M) to prevent HIV transmission
Prof Joseph Torresi	A personalised therapeutic approach for HBV associated liver cancer
<b>DIAGNOSTICS/PROGNOSTICS</b>	
A/Prof David Anderson	Development of quantitative HBV detection at point of care: proof of concept
A/Prof Rosemary Ffrench	Validation of VL-Plasma <sup>®</sup> device for use in HTLV proviral load and antibody testing
Jessica Howell	Utility of a rapid point of care ALT1 test to monitor disease progression and treatment eligibility in people living with hepatitis B
Prof Damian Purcell	HTLV-1c antibody and DNA assays to monitor prevention and disease prognosis
A/Prof Johnathan "Jack" Richards	Development of a point-of-care test for hepatitis B DNA
Dr Thomas Tu	Quantifying integrated and episomal HBV DNA in fine needle aspirate liver biopsies
<b>VACCINES / PREVENTION &amp; IMMUNOTHERAPY</b>	
Dr Rob Center	Immuno-silencing the HCV E2 glycoprotein non-neutralizing face
Prof Tony Cunningham	A new strategy for eradication of HIV using a combination of interferon and CAR T cells
Heidi Drummer	Low cost method of manufacture for hepatitis C vaccine
Dr. Celine Gubser	Using immune checkpoint blockade to reinvigorate exhausted T cells in people living with HIV (PLWH) on antiretroviral therapy (ART)
Dr. Pantelis (Andy) Poubourios	Immunogenicity of novel polyvalent HIV glycoprotein vaccines
Dr Nadia Warner	HBV neutralisation, and targeting EGFR-NTCP interaction as novel drug strategy
Dr Bruce D. Wines	Harnessing the glycan reactivity of PGT121-like bNABs for potent FcγRIII mediated killing of Env expressing target cells